These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

503 related articles for article (PubMed ID: 26520419)

  • 1. Significance of a minor high-grade component in a low-grade noninvasive papillary urothelial carcinoma of bladder.
    Reis LO; Taheri D; Chaux A; Guner G; Mendoza Rodriguez MA; Bivalacqua TJ; Schoenberg MP; Epstein JI; Netto GJ
    Hum Pathol; 2016 Jan; 47(1):20-5. PubMed ID: 26520419
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance in substaging ofT1 urinary bladder urothelial carcinoma on transurethral resection.
    Chang WC; Chang YH; Pan CC
    Am J Surg Pathol; 2012 Mar; 36(3):454-61. PubMed ID: 22261706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Maintenance Therapy with 3-monthly Bacillus Calmette-Guérin for 3 Years is Not Superior to Standard Induction Therapy in High-risk Non-muscle-invasive Urothelial Bladder Carcinoma: Final Results of Randomised CUETO Study 98013.
    Martínez-Piñeiro L; Portillo JA; Fernández JM; Zabala JA; Cadierno I; Moyano JL; Solsona E; Unda M; Beardo P; Rodríguez-Molina J; Chantada V; Palou J; Muntañola P; Alonso Dorrego JM; Pérez-Garcia FJ; Silva JM; Chesa N; Montesinos M; Ojea A; Madero R; Martínez-Piñeiro JA
    Eur Urol; 2015 Aug; 68(2):256-62. PubMed ID: 25794457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Managing noninvasive recurrences after definitive treatment for muscle-invasive bladder cancer or high-grade upper tract urothelial carcinoma.
    DiBianco JM; George AK; Su D; Agarwal PK
    Curr Opin Urol; 2015 Sep; 25(5):468-75. PubMed ID: 26125507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Adjuvant Intravesical Bacillus Calmette-Guérin Treatment on Patients with High-Grade T1 Bladder Cancer.
    Novotny V; Froehner M; Ollig J; Koch R; Zastrow S; Wirth MP
    Urol Int; 2016; 96(2):136-41. PubMed ID: 26789626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mixed low- and high-grade papillary urothelial carcinoma: histopathogenetic and clinical significance.
    Mai KT; Flood TA; Williams P; Kos Z; Belanger EC
    Virchows Arch; 2013 Oct; 463(4):575-81. PubMed ID: 23913166
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Invasive low-grade papillary urothelial carcinoma: a clinicopathologic analysis of 41 cases.
    Toll AD; Epstein JI
    Am J Surg Pathol; 2012 Jul; 36(7):1081-6. PubMed ID: 22510761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic Significance of Preoperative Urine Cytology in Low-grade Non-muscle-invasive Bladder Cancer.
    Kiyoshima K; Akitake M; Shiota M; Takeuchi A; Takahashi R; Inokuchi J; Tatsugami K; Yokomizo A; Eto M
    Anticancer Res; 2016 Feb; 36(2):799-802. PubMed ID: 26851042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term outcome of primary Papillary Urothelial Neoplasm of Low Malignant Potential (PUNLMP) including PUNLMP with inverted growth.
    Maxwell JP; Wang C; Wiebe N; Yilmaz A; Trpkov K
    Diagn Pathol; 2015 Mar; 10():3. PubMed ID: 25886613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative outcomes of primary, recurrent, and progressive high-risk non-muscle-invasive bladder cancer.
    Thomas F; Noon AP; Rubin N; Goepel JR; Catto JW
    Eur Urol; 2013 Jan; 63(1):145-54. PubMed ID: 22985746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The case for conservative management in the treatment of patients with non-muscle-invasive micropapillary bladder carcinoma without carcinoma in situ.
    Gaya JM; Palou J; Algaba F; Arce J; Rodríguez-Faba O; Villavicencio H
    Can J Urol; 2010 Oct; 17(5):5370-6. PubMed ID: 20974029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Papillary urothelial neoplasm of low malignant potential of the urinary bladder: clinicopathologic and outcome analysis from a single academic center.
    Lee TK; Chaux A; Karram S; Miyamoto H; Miller JS; Fajardo DA; Epstein JI; Netto GJ
    Hum Pathol; 2011 Nov; 42(11):1799-803. PubMed ID: 21777949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of tumor-associated macrophages count in human non-muscle-invasive bladder cancer treated by BCG immunotherapy.
    Ajili F; Kourda N; Darouiche A; Chebil M; Boubaker S
    Ultrastruct Pathol; 2013 Feb; 37(1):56-61. PubMed ID: 23383616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor multiplicity is an independent prognostic factor of non-muscle-invasive bladder cancer treated with Bacillus Calmette-Guerin immunotherapy.
    Ajili F; Manai M; Darouiche A; Chebil M; Boubaker S
    Ultrastruct Pathol; 2012 Oct; 36(5):320-4. PubMed ID: 23025650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment Strategy for Newly Diagnosed T1 High-grade Bladder Urothelial Carcinoma: New Insights and Updated Recommendations.
    Klaassen Z; Kamat AM; Kassouf W; Gontero P; Villavicencio H; Bellmunt J; van Rhijn BWG; Hartmann A; Catto JWF; Kulkarni GS
    Eur Urol; 2018 Nov; 74(5):597-608. PubMed ID: 30017405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ICUD-EAU International Consultation on Bladder Cancer 2012: Non-muscle-invasive urothelial carcinoma of the bladder.
    Burger M; Oosterlinck W; Konety B; Chang S; Gudjonsson S; Pruthi R; Soloway M; Solsona E; Sved P; Babjuk M; Brausi MA; Cheng C; Comperat E; Dinney C; Otto W; Shah J; Thürof J; Witjes JA;
    Eur Urol; 2013 Jan; 63(1):36-44. PubMed ID: 22981672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of gender on response to bacillus Calmette-Guérin therapy for patients with non-muscle-invasive urothelial carcinoma of the bladder.
    Boorjian SA; Zhu F; Herr HW
    BJU Int; 2010 Aug; 106(3):357-61. PubMed ID: 20002665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bladder urothelial neoplasms in pediatric age: experience at three tertiary centers.
    Berrettini A; Castagnetti M; Salerno A; Nappo SG; Manzoni G; Rigamonti W; Caione P
    J Pediatr Urol; 2015 Feb; 11(1):26.e1-5. PubMed ID: 25305695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Usefulness of pT1 substaging in papillary urothelial bladder carcinoma.
    Patriarca C; Hurle R; Moschini M; Freschi M; Colombo P; Colecchia M; Ferrari L; Guazzoni G; Conti A; Conti G; Lucianò R; Magnani T; Colombo R
    Diagn Pathol; 2016 Jan; 11():6. PubMed ID: 26791567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association.
    Kikuchi E; Fujimoto H; Mizutani Y; Okajima E; Koga H; Hinotsu S; Shinohara N; Oya M; Miki T;
    Int J Urol; 2009 Mar; 16(3):279-86. PubMed ID: 19207609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.